Clinical trialEPhase 1Not yet recruiting
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 30 September 2026
- Expected end
- 31 January 2030
- Enrollment
- 18 participants
- Sites
- 1
- Primary outcomes
- Incidence and Grading of Adverse Events (AEs) and Serious Adverse Events (SAEs)（Including CRS and ICANS）; Incidence and Determination of Dose-Limiting Toxicity (DLT) Related to CBG131; Maximum Tolerated Dose (MTD) and Optimal Dosage of CBG131（Determined by 3+3 Dose-Escalation Schema）
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try